KYTX
$8.80
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Intraday
Recent News
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their late-stage pipelines and upcoming catalysts have convinced institutional investors to build substantial positions. All four trade with unanimous or near-unanimous Buy ratings, a ... Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects
Kyverna Therapeutics (KYTX) is back in focus after unveiling positive topline data from its registrational KYSA-8 trial in stiff person syndrome, representing a key step toward a potential first-in-class autoimmune CAR T approval. See our latest analysis for Kyverna Therapeutics. The stock has whipsawed around the equity raise and trial headlines, with a 1 day share price return of minus 32.52 percent, a 90 day share price return of 37.92 percent, and a 1 year total shareholder return of...
Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation Data
US stocks look set to open higher in Wednesday's trading session as investors parse Tuesday's mixed
Investors Parse Jobs Data, Look Ahead to Inflation Report as US Futures Rise Pre-Bell
US stock futures are tracking higher in Wednesday's premarket session as investors dissect Tuesday's